Pembrolizumab Plus Quad-Shot Radiotherapy for Recurrent, Unresectable, or Metastatic Head and Neck Cancer

Дата публикации: 01-08-2026 00:00:00

This nonrandomized clinical trial examines the efficacy and toxic effects of immune checkpoint inhibitors in combination with quad-shot radiotherapy for patients with recurrent, unresectable, or metastatic head and neck squamous cell carcinoma.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Pathological response and exploratory assessment of pretreatment PD-L1 combined positive score after four cycles of neoadjuvant pembrolizumab plus chemotherapy in locally advanced head and neck squamous cell carcinoma: a retrospective cohort study	0	13.96	07-08-2026
2	Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR -Variant Non–Small Cell Lung Cancer	0	10	28-07-2026
3	Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma	0	13.22	28-11-2023
4	Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer	0	5	18-06-2026
5	Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer	0	14.28	01-01-2025
6	Individualized Stereotactic Ablative Radiotherapy for Lung Tumors	0	6.6	01-11-2023
7	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
8	Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC	0	5	30-06-2026
9	Superselective intra-arterial cisplatin infusion and concomitant radiotherapy (RADPLAT) for maxillary sinus squamous cell carcinoma: an institutional experience of 118 cases	0	20.34	10-08-2026

Классификация: Пресс-релизы. Схожих патентов: 0. Схожих новостей: 9. Тональность: 0. Информативность: 8.64. Источник: jamanetwork.com.